Piper Sandler Adjusts Price Target on Viatris to $14 From $13

The FDA approved phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) for presbyopia in October 2026. The drug reduces pupil size via a sympatholytic mechanism, avoiding ciliary muscle engagement. Clinical trials showed 27.2% of patients gained near vision without losing distance vision. Experts discuss its unique mechanism and potential patient benefits compared to other presbyopia treatments.

Viatris (VTRS) has launched a tender offer to acquire Pacira BioSciences (PCRX) for $36.50 per share in cash. The offer, set to expire on November 16, 2026, is part of a merger agreement signed on October 8, 2026. Pacira's board has recommended shareholders accept the offer. The transaction is subject to regulatory approvals and shareholder participation.

Viatris, a global healthcare company, has initiated a tender offer to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, according to an official statement.

Viatris Inc. (VTRS) subsidiary launched a tender offer to acquire Pacira BioSciences (PCRX) for $36.50 per share in cash. The offer expires November 16, 2026, and requires over 50% of shares to be tendered. Pacira's board recommends shareholders accept the offer. The merger does not need shareholder approval and is subject to antitrust clearance.

Viatris Inc. (VTRS) has initiated a cash tender offer to acquire all shares of Pacira BioSciences at $36.50 per share. The offer, which expires Nov. 16, 2026, is contingent on a minimum 50% acceptance and HSR clearance. According to Viatris, the deal is subject to regulatory approval and other conditions.

Viatris Inc. (VTRS) has launched a tender offer to acquire all shares of Pacira BioSciences, Inc. (PCRX) for $36.50 per share in cash. The offer is part of a merger agreement, with Pacira's board recommending shareholders accept the deal. The offer expires on Nov. 16, 2026, unless extended or terminated.